Bio-Rad Laboratories, Inc. Class A Common Stock vs Invesco Solar ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Invesco Solar ETF trades at $55.17. Which is the better fit depends on your goals.
| BIO | TAN | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Sector/Thematic |
52-Week High | $339.75 | $73.95 |
52-Week Low | $241.71 | $36.07 |
Enterprise Value | $7.85B | — |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Invesco Solar ETF (TAN) trades at $53.12, down 3.35% amid a bearish technical signal with 18 sell indicators. The fund focuses on utility-scale solar and grid technology, benefiting from AI-driven electricity demand but facing headwinds from policy uncertainty and supply chain costs. Recent news highlights both long-term growth potential and near-term volatility.
Outlook is mixed: strong structural demand for clean energy supports long-term growth, but regulatory risks and technical weakness pose challenges. Investors should weigh exposure to solar's AI-driven expansion against policy sensitivity and current bearish momentum.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →